The disclosure also contemplates the use of one or more of the formulations or compositions, in the manufacture of medicaments for treating, abating, reducing, or ameliorating the symptoms of a disease, dysfunction, or disorder in a mammal, such as a human that has, is suspected of having, or at risk for developing an auris interna disorder
The addition of CJC-1295 with Ipamorelin and BPC-157 peptides can further optimize cognitive function, promoting mental clarity, focus, and overall well-being
Timeline of expected results Understanding when to expect results prevents premature protocol abandonment and helps researchers assess whether their approach is working
BPC-157 Taper: Return to 250 mcg daily for final 4 weeks (Weeks 912)